Resource Library
Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.
Related Resources
June 1, 2024
Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)
American Society of Clinical Oncology (ASCO) 2024
Liquid Tumors
Solid Tumors
Read More
October 16, 2023
Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia
10th International MDM2 Workshop
Liquid Tumors
Solid Tumors
Read More
October 14, 2023
The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Solid Tumors
Read More
June 6, 2023
Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors
European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
Read More
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
Read More
October 27, 2022
Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors
5th Annual Targeted Protein Degradation (TPD) Summit
Liquid Tumors
Solid Tumors
Read More
April 7, 2022
KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
American Association for Cancer Research Annual Meeting
Liquid Tumors
Solid Tumors
Read More